Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Acarix AB's average basic shares outstanding for the quarter that ended in Mar. 2026 was 1,172.30 Mil.
Acarix AB (OTCPK:ACIXF) Shares Outstanding (Basic Average) Explanation
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Be Aware
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Acarix AB Shares Outstanding (Basic Average) Related Terms
Acarix AB Shares Outstanding (Basic Average) Historical Data
* Premium members only.
The historical data trend for Acarix AB's Shares Outstanding (Basic Average) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acarix AB Shares Outstanding (Basic Average) Chart
Acarix AB Shares Outstanding (Basic Average) Calculation
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.
What does a Shares Outstanding (Basic Average) of 1,172.30 Mil mean?
Acarix AB (ACIXF) has a Shares Outstanding (Basic Average) of 1,172.30 Mil as of Mar. 2026. The average shares outstanding over two periods not accounting for dilutive securities like convertible bonds. View historical data on Acarix AB and its competitors.
Is Acarix AB's Shares Outstanding (Basic Average) too high?
Acarix AB's current Shares Outstanding (Basic Average) is 1,172.30 Mil. Overall, Acarix AB has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Acarix AB's Shares Outstanding (Basic Average) compare to ABT and SYK?
Acarix AB's Shares Outstanding (Basic Average) of 1,172.30 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (Basic Average) for a Medical Devices & Instruments company?
A good Shares Outstanding (Basic Average) depends on the Medical Devices & Instruments industry context. However, Shares Outstanding (Basic Average) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (Basic Average) mean?
A high Shares Outstanding (Basic Average) can signal that a stock is expensive relative to its fundamentals. The average shares outstanding over two periods not accounting for dilutive securities like convertible bonds. View historical data on Acarix AB and its competitors. Acarix AB's current Shares Outstanding (Basic Average) is 1,172.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acarix AB stock overvalued right now?
Based on GuruFocus' analysis, Acarix AB (ACIXF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.03 — trading 45% above its estimated fair value. The current Shares Outstanding (Basic Average) is 1,172.30 Mil. Acarix AB's overall GF Score™ is 47/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (Basic Average) calculated?
Shares Outstanding (Basic Average) is calculated from a company's financial statements. For Acarix AB (ACIXF), the current Shares Outstanding (Basic Average) is 1,172.30 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Acarix AB (ACIXF) Overvalued in 2026?
Based on GuruFocus' analysis, Acarix AB stock appears to be overvalued.
The current stock price of $0.03 is trading 45% above its estimated GF Value™ of $0.02.
GuruFocus considers Acarix AB to be Significantly Overvalued.
Key valuation signals for ACIXF:
Shares Outstanding (Basic Average): 1,172.30 Mil
GF Value™: $0.02 vs. price of $0.03 (45% above fair value)
No single metric tells the full story. See the ACIXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acarix AB is a Swedish medical technology company that develops solutions for rapid AI-based exclusion of coronary artery disease (CAD). Its CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. Acarix recommends the CADScor System as a first-line diagnostic tool that uses sensitive acoustics and computational processing to analyze coronary blood flow to rule out coronary artery disease (CAD), with a majority certainty at the point of care. Geographically, the company generates maximum revenue from the United States, and the rest from Germany, Sweden, Iraq, and other regions.
47GF Score
Get the complete analysis for ACIXF
Shares Outstanding (Basic Average) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACIXF has been successfully added to your 
